RESCEU Work Package 2 representatives met with the EMA Vaccine Working Party (VWP) on June 7th at the EMA in London, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies.

RESCEU representatives and EMA VWP members agreed that Work Package 2 outputs will be of importance to the EMA as they will: highlight target groups for interventions, inform research investment prioritisation, inform the design of clinical trials (such as by aiding in the selection of appropriate outcomes and case/severity definitions), and produce “baseline” burden data that will help assess the impact of future interventions. RESCEU Work Package 2 will continue to engage with the EMA VWP, including sharing the results of the RSV burden estimates.

RESCEU aims to investigate serious lung infections caused by respiratory syncytial virus (RSV) that particularly affect babies and older people, and those with weakened immune systems, including cancer patients and people with chronic lung diseases such as emphysema.

The RESCEU project has an initial budget of €29M distributed across 18 partner from universities, clinical centres, health organisations, and pharmaceutical companies, sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU).